Tabula Rasa HealthCare, Inc. is a healthcare technology company advancing the safe use of medications by creating solutions designed to empower pharmacists, providers, and patients to optimize medication regimens. Our advanced proprietary technology, MedWise®, identifies causes of and risks for medication-related problems, including adverse drug events (“ADEs”), so that healthcare professionals can minimize harm and reduce medication-related risks. Our software and services help drive valued-based care by improving patient outcomes and lowering healthcare costs through reduced hospitalizations, emergency department visits, and healthcare utilization. Our vision and mission are supported by our experienced leadership team, our significant investments in our technology, services, and people, and partnerships with our healthcare clients including health plans and provider organizations to manage the most complex and vulnerable individuals.
Company profile
Ticker
TRHC
Exchange
Website
CEO
Calvin Knowlton
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Tabula Rasa HealthCare Group, Inc. • DM Acquisition Pty Ltd • DoseMe Holdings Pty Ltd • DoseMe Pty Ltd • TRHC TPA, LLC ...
TRHC stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
17 Nov 23
EFFECT
Notice of effectiveness
17 Nov 23
EFFECT
Notice of effectiveness
17 Nov 23
EFFECT
Notice of effectiveness
17 Nov 23
EFFECT
Notice of effectiveness
17 Nov 23
EFFECT
Notice of effectiveness
17 Nov 23
EFFECT
Notice of effectiveness
17 Nov 23
EFFECT
Notice of effectiveness
17 Nov 23
EFFECT
Notice of effectiveness
17 Nov 23
15-12G
Securities registration termination
13 Nov 23
Transcripts
TRHC
Earnings call transcript
2023 Q1
9 May 23
TRHC
Earnings call transcript
2022 Q4
7 Mar 23
TRHC
Earnings call transcript
2022 Q3
4 Nov 22
TRHC
Earnings call transcript
2022 Q2
5 Aug 22
TRHC
Earnings call transcript
2022 Q1
6 May 22
TRHC
Earnings call transcript
2021 Q4
25 Feb 22
TRHC
Earnings call transcript
2021 Q3
5 Nov 21
TRHC
Earnings call transcript
2021 Q2
7 Aug 21
TRHC
Earnings call transcript
2021 Q1
9 May 21
TRHC
Earnings call transcript
2020 Q4
24 Feb 21
Latest ownership filings
4
Ronald Paul Mitchell
14 Nov 23
4
Michael J. Purcell
14 Nov 23
4
Jonathan David Schwartz
14 Nov 23
4
Pamela Schweitzer
14 Nov 23
4
Dennis Helling
14 Nov 23
4
Michael Anthony Bruno
14 Nov 23
4
Michael Greenhalgh
14 Nov 23
4
Brian W Adams
14 Nov 23
4
DEREK C SCHRIER
14 Nov 23
4
Thomas Cancro
14 Nov 23
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 62.81 mm | 62.81 mm | 62.81 mm | 62.81 mm | 62.81 mm | 62.81 mm |
Cash burn (monthly) | 1.46 mm | (no burn) | 3.20 mm | 5.07 mm | (no burn) | 427.50 k |
Cash used (since last report) | 14.36 mm | n/a | 31.51 mm | 49.86 mm | n/a | 4.21 mm |
Cash remaining | 48.45 mm | n/a | 31.30 mm | 12.95 mm | n/a | 58.61 mm |
Runway (months of cash) | 33.2 | n/a | 9.8 | 2.6 | n/a | 137.1 |
Institutional ownership, Q3 2023
73.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 87 |
Opened positions | 37 |
Closed positions | 32 |
Increased positions | 12 |
Reduced positions | 22 |
13F shares | Current |
---|---|
Total value | 163.16 bn |
Total shares | 19.82 mm |
Total puts | 36.50 k |
Total calls | 13.60 k |
Total put/call ratio | 2.7 |
Largest owners | Shares | Value |
---|---|---|
Indaba Capital Management | 6.52 mm | $67.24 bn |
First Trust Portfolios | 3.47 mm | $52.01 mm |
Glazer Capital | 1.05 mm | $10.82 bn |
Vanguard | 899.51 k | $9.27 bn |
Beryl Capital Management | 591.75 k | $6.10 bn |
Berry Street Capital Management | 550.00 k | $5.67 bn |
BLK Blackrock | 371.39 k | $3.83 bn |
Qube Research & Technologies | 368.22 k | $3.80 bn |
Gabelli Funds | 355.66 k | $3.67 bn |
Kennedy Capital Management | 300.85 k | $3.10 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Nov 23 | Brian W Adams | Common Stock | Sale back to company | Dispose D | No | No | 0 | 292,708 | 0.00 | 0 |
3 Nov 23 | Brian W Adams | Common Stock | Sale back to company | Dispose D | No | No | 0 | 169,570 | 0.00 | 292,708 |
3 Nov 23 | Brian W Adams | Common Stock | Sale back to company | Dispose D | No | No | 0 | 55,556 | 0.00 | 462,278 |
3 Nov 23 | Brian W Adams | Common Stock | Sale back to company | Dispose D | No | No | 0 | 249,477 | 0.00 | 517,834 |
3 Nov 23 | Brian W Adams | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 13.78 | 38,270 | 527.36 k | 0 |
3 Nov 23 | Brian W Adams | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 13.78 | 1,077 | 14.84 k | 0 |
3 Nov 23 | Brian W Adams | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 14.23 | 21,350 | 303.81 k | 0 |
3 Nov 23 | O'Brien Kathrine | Common Stock | Sale back to company | Dispose D | No | No | 0 | 25,641 | 0.00 | 0 |
3 Nov 23 | O'Brien Kathrine | Common Stock | Sale back to company | Dispose D | No | No | 0 | 50,169 | 0.00 | 25,641 |
3 Nov 23 | O'Brien Kathrine | Common Stock | Sale back to company | Dispose D | No | No | 0 | 20,879 | 0.00 | 75,810 |